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and one of the most aggressive malignancies. The median
survival is only 5 months and fewer than 20% of patients
survive 1 year after diagnosis.1 An optimal treatment pro-
tocol remains to be established. Nevertheless, combined
multimodal therapy with surgery, radiotherapy, and
chemotherapy is thought to be effective. We report a pa-
tient with anaplastic thyroid carcinoma which was nearly
resolved following multimodality treatment.
A 64-year-old man presented with a rapid enlarged
neck mass in 4 months, accompanied with hoarseness. A
5 cm  6 cm firm right thyroid mass was found. Neck
computed tomography showed a heterogeneously-
enhancing tumor mass lesion (5.4 cm  6.4 cm  4.5 cm)
with necrotic change and multiple coarse calcifications
over the lower position of the right lobe of the thyroid
gland, with downward and regional extension. He received
surgery on August 27, 2013, but only partial excision of the
tumor could be performed. Pathology reported anaplastic
thyroid carcinoma. No regional lymph nodes or distant
metastasis were detected. Initial staging was stage IVB.
Thyroid echography in September 2013 showed a tumor
with irregular, infiltrated border and carotid artery
encasement. (Fig. 1A). The first cycle of chemotherapy
started on September 6, 2013 (doxorubicin 60 mg/m2 plusConflicts of interest: All authors declare no conflicts of interest.
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0929-6646/Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medicalcisplatin 60 mg/m2). Neck radiation (66 Gy/30 fractions)
was started on September 17, 2013. A second course of
chemotherapy was given on October 5, 2013. The major
toxicity was febrile neutropenia during the treatment
course, which resolved after G-CSF was administered. Se-
rial follow-up showed tumor shrinkage under thyroid
echography (Fig. 1B) until January 2014, and nearly dis-
appeared at that time (Fig. 1C).
Treatment of anaplastic thyroid cancer is a challenge to
all endocrinologists and endocrine surgeons, because
there is currently no consensus on effective treatment.
Surgery is generally the first step of treatment. Most
studies showed that complete resection of the tumor im-
proves survival, however, it is only feasible in a minority of
patients.1 Radiotherapy can improve local control, but
does not significantly improve the median survival.1
Doxorubicin and cisplatin every 3 weeks were proved to
be superior to doxorubicin alone, and the response rate
ranged from 25% to 50% in different studies.2,3 A study in
Japan found that weekly induction chemotherapy with
paclitaxel also improved overall survival in stage IVB pa-
tients (response rate: 33%), but not in stage IVC patients.4
There is still debate about the best choice of chemo-
therapy agent.
Derbel et al3 identified the poor prognostic factors
(including performance status, tumor diameter, distant
metastasis, tracheal infiltration, >65 years old, male,
acute symptoms at diagnosis, white blood cell count) which
are associated with overall survival and progression free
survival. They also suggested aggressive multimodal ther-
apy for patients with three or fewer poor prognostic factors
and tried to increase the chance of survival.3Association. All rights reserved.
Figure 1 (A) Residual tumor at right lobe of the thyroid after surgery; (B) tumor shrinkage after radiotherapy and two cycles of
chemotherapy; and (C) nearly resolved tumor.
898 Y.-T. Tseng, T.-C. ChangIn our patient, we found a dramatic change under ul-
trasound imaging after multimodality treatment, which
may be worth further study.
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